Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
ID: 357020Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357020

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-063.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for Research Project Grants (R01) aimed at the development of screening assays for drug candidates targeting psychiatric disorders. The primary objectives of this initiative are to stimulate research in the discovery and development of novel small molecules that can potentially treat mental illnesses, as well as to validate compounds that demonstrate desired biological activity through rigorous screening processes. This funding is crucial for advancing therapeutic options for conditions such as depression, schizophrenia, and PTSD, and it encourages applicants to align their proposals with the National Institute of Mental Health (NIMH) priorities. Interested applicants must submit their proposals by May 7, 2026, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-063-Full-Announcement.html
    PAR-25-063.html
    The National Institutes of Health (NIH), through the National Institute of Mental Health (NIMH), is offering funding for Research Project Grants (R01) aimed at developing screening assays for drug candidates treating mental illnesses. The initiative focuses on validating "hits," compounds that exhibit desired biological activity in initial screenings and confirmed in follow-up assays. The funding opportunity includes three research stages: assay development, primary screening implementation, and hit validation. Applications must address the project's significance and innovation and delineate plans for research rigor, feasibility, and organizational capacity. Eligible entities include higher education institutions, nonprofits, for-profit organizations, and governmental bodies, with a maximum project period of five years. The funding's purpose is to stimulate research into novel therapeutics for psychiatric conditions such as depression, schizophrenia, and PTSD. Applicants are encouraged to align their proposals with NIMH priorities and include appropriate data management and sharing plans post-approval. The application submission process involves adherence to the NIH application guide, with strict compliance to improve the likelihood of funding success.
    Similar Opportunities
    Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)," aimed at advancing research in drug discovery for psychiatric disorders. The initiative focuses on the development and validation of screening assays to identify effective chemical hits for conditions such as depression, bipolar disorder, and schizophrenia, encouraging innovative approaches in mental health research. This grant opportunity is open to a wide range of eligible applicants, including higher education institutions and community-based organizations, with no budget limits and a maximum project period of five years. Interested parties can find more information and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with applications accepted until May 7, 2026.
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the National Cooperative Drug/Device Discovery/Development Groups (NCDDG) funding opportunity, aimed at advancing innovative therapies for mental disorders through cooperative agreements. This initiative encourages applications focused on the discovery, preclinical development, and proof of concept testing of new pharmacological agents and neuromodulatory devices, with a strong emphasis on partnerships between academia and industry. The program is designed to facilitate the transition of drug and device solutions from discovery to early human trials, addressing critical mental health challenges. Interested applicants must comply with NIH registration and submission requirements, with application deadlines beginning on January 25, 2025, and funding awards potentially lasting up to five years. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-352.html.
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)," aimed at advancing the discovery and development of innovative treatments for mental disorders, including substance use disorders and alcohol use disorder. This initiative encourages collaborative efforts between academia and industry to support multidisciplinary research projects that focus on early-stage human studies and the development of novel therapeutic candidates and neuromodulation tools. The program is designed to complement private sector efforts and emphasizes the importance of data sharing and innovative approaches to mental health treatment challenges. Interested applicants must adhere to specific eligibility criteria and application instructions, with a submission opening date of January 25, 2025, and a total project period not exceeding five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-353.html.
    Addressing Methodological Challenges with Clinical Trials of Psychotomimetic Agents
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Addressing Methodological Challenges with Clinical Trials of Psychotomimetic Agents," aimed at soliciting research applications that tackle the methodological issues associated with clinical trials involving psychotomimetic agents (PMAs). The focus of this initiative is to enhance the understanding of the therapeutic effects of PMAs, such as psilocybin and MDMA, which have shown potential benefits for mental health disorders like depression and anxiety, thereby increasing confidence in clinical trial outcomes. The estimated total program funding is $5 million, with approximately five awards anticipated, and interested applicants are encouraged to engage with the FDA prior to submission to ensure compliance with regulatory requirements. For further inquiries, potential applicants can contact Jonathan Sabbagh, Ph.D., at jonathan.sabbagh@nih.gov or by phone at 301-793-3534. The synopsis is expected to be posted on September 3, 2025, with applications closing on November 3, 2025, and awards anticipated by July 1, 2026.
    Clinical Studies of Mental Illness (Collaborative R01) (Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Clinical Studies of Mental Illness (Collaborative R01)" aimed at supporting multidisciplinary clinical studies focused on mental health, particularly in areas such as genetics, biomarkers, and various mental illnesses. This initiative encourages collaboration across multiple sites to enhance sample sizes and diversity in participant recruitment, specifically targeting health disparity populations. The program allows for a project period of up to five years with no explicit budget limits, although proposed budgets must be well justified. Interested applicants, including various educational and nonprofit institutions, should submit their applications by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For more details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-23-050.html.
    Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)" aimed at supporting research into novel small molecules that can modulate biological targets relevant to mental health, aging, drug abuse, and eye diseases. The initiative seeks to stimulate the discovery and development of in vivo chemical probes, requiring applicants to have validated starting compounds for optimization and bioassays to test new analogs. This funding is crucial for advancing the understanding of brain disease mechanisms and emphasizes projects that provide insights into significant biological processes. Interested applicants can submit proposals until January 7, 2027, with no budget limit specified, although actual needs must be indicated. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at NIH Grants.
    Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) for the development and screening of assays aimed at discovering small molecules that can serve as chemical probes, drugs, or immunomodulators. This initiative seeks to support research that elucidates disease biology and therapeutic targets, particularly focusing on cancer-related applications, including the development of assays, high-throughput screening, hit validation, and optimization of lead compounds. The opportunity is open to a wide range of eligible applicants, including educational institutions, nonprofits, and tribal organizations, with no cost-sharing requirement and a project period of up to three years. Interested parties should submit their applications electronically through Grants.gov by the deadline of September 7, 2026, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS), a federal grant aimed at supporting early-career scientists in advancing their research in mental health. This initiative seeks to foster innovative clinical, translational, or basic research that can significantly enhance the understanding, diagnosis, treatment, or prevention of mental health disorders. With an estimated total program funding of $3 million and the expectation of awarding six grants, this opportunity is designed for small businesses committed to impactful research in the field. Interested applicants can reach out to Dr. Eric R. Murphy at eric.murphy@nih.gov or by phone at 301-443-9230 for further information, with the anticipated synopsis posting date on September 20, 2025, and a closing date of October 20, 2025.
    Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators" through the National Cancer Institute (NCI). This initiative aims to support research focused on the identification and development of small molecules that can elucidate cancer biology and contribute to therapeutic advancements. The funding is intended for various eligible applicants, including educational institutions and non-profit organizations, with a flexible budget and a project duration of up to three years. Key deadlines include an application submission window starting January 5, 2025, and a closing date of September 7, 2026. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-153.html.
    Discovery of in vivo Chemical Probes for the Nervous System
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting the discovery of in vivo chemical probes for the nervous system, specifically targeting novel brain mechanisms. This initiative, led by the National Institute on Aging (NIA) in collaboration with the National Eye Institute (NEI), the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH), seeks applicants who possess validated starting compounds for chemical optimization and bioassays to explore new analog compounds. The focus will be on developing small molecules that can enhance understanding of biological processes relevant to brain diseases, with an emphasis on innovative biological targets. Interested applicants can reach out to Dr. Paul G. Grothaus at grothausp@mail.nih.gov or call 240-688-6634 for further information, with the estimated synopsis posting date set for February 26, 2026, and a projected award date of April 5, 2027.